Epidemiology Study - Overview

Epilepsy Study Objective:

To determine the prevalence and incidence of Epilepsy among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Epilepsy within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Epilepsy Study USP:

• This epidemiological study on Epilepsy stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Epilepsy related health problems.

• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Epilepsy but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Epilepsy cases.

Epilepsy related Study Overview:

The study Defines Epilepsy as an advanced form of disease. The significance of studying Epilepsy epidemiology is due to its increasing prevalence in different age populations.

Epilepsy Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Epilepsy cases (e.g., clinical examination) and demographic data (age, sex, ethnicity).

Epilepsy Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Epilepsy and potential risk factors (e.g., age, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Epilepsy study summary:

Epilepsy use disorder study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Obesity worldwide.

Epilepsy Disease overview:

Epilepsy is a neurological condition, chronic noncommunicable disease of brain characterised by unprovoked and recurrent seizures. Seizures are bursts of abnormal electrical activity in brain suddenly, causing changes in sensation, behaviours, awareness and movement of muscles.

Worldwide 50 million people are suffering with epilepsy, one of the most common global neurological diseases. Low- and middle-income countries comprise nearly 80% of people with epilepsy. In 2021, 24,220,856 patients were found to having epilepsy, 307.38 per 100,000 persons was age-standardized prevalence rate (ASPR) of epilepsy and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons. The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population.

Various treatment options are available for epilepsy including, anti-Epileptic Drug (AED), or A device called a vagus nerve stimulator. Key market players manufacturing therapeutics for the treatment of epilepsy are as follows; LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Abbott Laboratories (U.S.)

Epilepsy Demographic and Environmental Risk Factors:

Age and sex: In 2021, rate of prevalence for epilepsy was highest in males than females, but at age of 70 and above the rate was seen to be higher in females than males. Highest prevalence globally was seen for 15 to 49 age group with 11,483,777 patients accounting 47.41 % of all age group, which includes 6,099,124 males and 5,384,652 females. Highest age specific prevalence rate was observed for people aged 70 and more. Incidence rate for children in age 0 to 14 years is higher compared to other age groups. Highest mortality rates were seen in 70 and more age group showing male mortality per 100,000 people higher than that of females.

Ethnicity: in one of the studies conducted in Columbia has reported that lifetime prevalence of epilepsy at 0.77% in whites and 2.13% in blacks, people with less than high school education had prevalence of 3.4% indicating socioeconomic factors affecting the rates.

Risk Factors causing Epilepsy: Risk factors causing epilepsy include alcohol use, more prevalent in high income countries like Australia, Western Europe, Eastern Europe. Alcohol abuse causes neurological dysfunction and risk of epileptic seizures increases, heavy drinking can cause damage to brain structure, increasing risk of epilepsy, moreover alcohol related accidents and injuries can cause brain trauma again increasing chances of epilepsy.

Other than alcohol, lifestyle factors such as sleep deprivation is common cause of seizures, inactive lifestyle and poor dietary habits can cause obesity which can link to chronic conditions like epilepsy and smoking can show effect of nicotine and other tobacco compounds on nervous system, which is also a major risk factor. Environmental toxins exposures or infectious agents can increase the risk of epilepsy in certain regions. Differences in cultures might further impact perceptions of epilepsy and healthcare-seeking behaviours, affecting treatment outcomes.

Epilepsy Market Scope:

Drivers: Increasing Incidence of PTE to Drive Market Growth-The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand. In addition, brain damage that can cause post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can fuel demand in the epilepsy industry. The worldwide demand for epilepsy is also influenced epilepsy market by primary factors such as developing experimental medicines, the arrival of new drugs in developed regions and the prevalence of neurological disorders such as meningitis and tumors. This rise is further fueled by an improvement in healthcare prices and an increase in disposable income.

Growing Adoption of Advanced Imaging Technology for Early Diagnosis Contributes to Market Growth-Emerging trends such as businesses focused on designing innovative treatments for refractory epilepsy and doctors requiring higher effectiveness medications is increasing the R&D investments towards the epilepsy market. The growing adoption of rational polytherapy and the advanced imaging technology for early diagnosis also contributes to market growth. Moreover, the adoption of advanced digital healthcare models such as mHealth and telemedicine is likely to create growth opportunities for the epilepsy market.

Restraints: Rise in Medication Costs Likely to Impede Market-On the other hand, the demand expansion is hampered by a time-consuming prescription approval process, and rising medication costs. Moreover, the low awareness about the challenges of epilepsy can also hinder the epilepsy market growth. Infact, consumers are increasingly petitioning gaming companies and social media platforms to include epileptic warnings.